Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. SPY
3. LGND
4. ONON
5. PSKY
6. META
7. VRTX
8. MA
9. ACN
10. IAUX

Go back to Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance

Integra LifeSciences (IART) PT Raised to $75 at Truist Securities

February 18, 2021 4:21 PM EST

Truist Securities analyst Kaila Krum raised the price target on Integra LifeSciences (NASDAQ: IART) to $75.00 (from $70.00) while maintaining a Buy rating.

The analyst comments "Integra announced Q4 2020 results, with revenue of $389 million coming in at the high end of its preliminary range that... More

Integra LifeSciences (IART) Tops Q4 EPS by 11c; Offers 1Q EPS/Revenue Guidance Below Consensus, FY21 Revenues Views Below Consensus

February 18, 2021 6:26 AM EST

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $388.6 million versus the consensus estimate of $388.58 million.

Fourth Quarter 2020

Reported revenues were $388.6 million, representing a decrease of 1.6% on a reported basis and a decrease of 1.5% on an organic basis compared to the fourth quarter 2019.Fourth quarter revenues increased 5.0% compared to the third quarter of 2020.GAAP earnings per diluted share were $1.09, compared to $0.18 in the fourth quarter 2019.Adjusted earnings per diluted share were $0.84, compared to... More